Henriksson M, Lundgren F, Carlsson P
Centre for Medical Technology Assessment, Linköping University, Linköping, Sweden.
Br J Surg. 2008 Jun;95(6):714-20. doi: 10.1002/bjs.6157.
Long-term health outcomes and costs are important when deciding whether a strategy of carotid endarterectomy in addition to best medical management should be recommended for patients with asymptomatic carotid artery stenosis. This study investigated the cost-effectiveness of such a strategy compared with a strategy of best medical management alone.
Based on data from the randomized Asymptomatic Carotid Surgery Trial (ACST), a national vascular database and other published sources, expected costs and health outcomes in terms of quality-adjusted life years (QALYs) of both treatment strategies were estimated using decision-analytical modelling. Cost-effectiveness was established for a Swedish setting from a societal perspective.
Base-case analysis showed that the incremental cost per QALY of a strategy with carotid endarterectomy for 65- and 75-year-old men (women) was 34,557 euros (311,133 euros) and 58,930 euros (779,776 euros) respectively. Sensitivity analyses indicated that the duration of the treatment effect after 5 years of follow-up in the ACST was important for the cost-effectiveness results.
Carotid endarterectomy in addition to best medical management can be considered cost-effective in men aged 73 years or less but is less likely to be cost-effective in older men or in women.
在决定对于无症状性颈动脉狭窄患者是否应推荐除最佳药物治疗外联合颈动脉内膜切除术的策略时,长期健康结局和成本非常重要。本研究调查了该策略与单纯最佳药物治疗策略相比的成本效益。
基于随机无症状颈动脉手术试验(ACST)的数据、一个国家血管数据库及其他已发表资料,采用决策分析模型估计两种治疗策略在质量调整生命年(QALY)方面的预期成本和健康结局。从社会角度确定瑞典环境下的成本效益。
基础病例分析显示,对于65岁和75岁男性(女性),采用颈动脉内膜切除术策略每获得一个QALY的增量成本分别为34,557欧元(311,133欧元)和58,930欧元(779,776欧元)。敏感性分析表明,ACST随访5年后治疗效果的持续时间对成本效益结果很重要。
除最佳药物治疗外联合颈动脉内膜切除术对于73岁及以下男性可认为具有成本效益,但对于老年男性或女性则不太可能具有成本效益。